List of Excipients in Branded Drug DORAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galt Pharmaceuticals LLC	DORAL	quazepam	61825-165	FD&C YELLOW NO. 6	2028-06-03
Galt Pharmaceuticals LLC	DORAL	quazepam	61825-165	LACTOSE	2028-06-03
Galt Pharmaceuticals LLC	DORAL	quazepam	61825-165	MAGNESIUM STEARATE	2028-06-03

Last updated: July 30, 2026

Doral (Quazepam) Excipient Strategy and Commercial Opportunities: Compatibility, Market Gaps, and IP Barriers

Doral (quazepam) is an oral benzodiazepine hypnotic with a narrowed U.S. competitive set centered on orange-book-linked drug product IP and generic market access constraints tied to listed strengths, manufacturability, and formulation equivalence. Commercial opportunities cluster around (1) excipient-enabled manufacturing robustness (powder flow, granulation or direct compression, dissolution), (2) reformulation that stays within narrow generic equivalence windows while enabling new product line extensions (different strength, packaging, or solid-state platform), and (3) distribution and acquisition strategies where incumbents have limited supply continuity.

Because Doral is a small-molecule, solid oral product, the highest-value excipient strategy is risk reduction for bioequivalence and regulatory defensibility rather than large therapeutic innovation. The decision tree is largely driven by which excipients are already “locked in” by existing drug product specs and what new excipient switches would require bridging studies to support an NDA supplement or an ANDA amendment.

---

What excipient profile does Doral (quazepam) use, and why does it matter for reformulation?

Featured snippet answer: Excipient choices in Doral are primarily determined by solid oral processing needs (blendability, compression behavior, tablet integrity) and by dissolution and stability performance under shelf-life conditions.

Key excipient functions relevant to quazepam tablets/capsules

Even when the active is constant, excipient strategy changes:

• Dissolution rate: wetting agents, solubilizers, and disintegrants control how fast quazepam dissolves and reaches bioequivalent concentration-time profiles.
• Solid-state stability: antioxidants, buffering agents (if needed), and moisture control excipients can reduce degradation pathways.
• Manufacturing yield and robustness: binders and fillers affect granulation consistency, tablet hardness, capping, and batch-to-batch variability.
• Regulatory bridge burden: swapping excipients can trigger dissolution and bioequivalence re-testing if changes affect CQA-linked properties (particle size distribution, dissolution similarity, and moisture sensitivity).

Typical formulation “hot spots” for benzodiazepine hypnotics

For orally dosed, poorly soluble to moderately soluble small molecules, the most commercially sensitive CQA links are:

• dissolution medium sensitivity
• disintegration time distribution
• tablet hardness and friability
• moisture uptake and degradation kinetics

---

Which excipients are most likely to be change-sensitive for Doral generics or 505(b)(2) products?

Featured snippet answer: Excipients that drive dissolution and moisture behavior are the highest change-sensitive levers.

Change-sensitive categories

1. Disintegrants (fast vs. sustained)

   • Faster disintegration often increases early dissolution, shifting Cmax.
   • Different disintegrants can change tablet disintegration mechanics and water uptake kinetics.

2. Solubilizers or surfactants (if present)

   • Surfactant level affects wettability and micellar solubilization.
   • Surfactant identity can shift dissolution profile slope, risking BE failure.

3. Binders and granulation aids

   • Change in binder affects granule strength, porosity, and disintegration under GI conditions.
   • Direct compression vs. wet granulation changes powder flow and tablet tensile strength.

4. Lubricants

   • Lubricant type and concentration affect tablet ejection, surface lubrication, and dissolution by altering surface film characteristics.
   • Magnesium stearate grade and level are frequent failure points in BE due to hydrophobic film effects.

5. Moisture-control system

   • Hygroscopic fillers, desiccant strategy, and coating system can alter stability and dissolution.

---

What “excipient strategy” improves manufacturability for quazepam without jeopardizing bioequivalence?

Featured snippet answer: The safest strategy is an excipient equivalence map that preserves dissolution slope and water uptake while improving process capability (blend uniformity, granulation reproducibility, compression performance).

Operational excipient playbook

• Optimize disintegration mechanism rather than identity: use disintegrant systems that match the incumbent dissolution kinetics, then fine-tune concentration to align with release specs.
• Preserve lubricant hydrophobicity profile: if changing lubricant, do it with controlled margin and justify dissolution similarity.
• Use a design-of-experiments (DoE) bridge for CQA: link excipient variables to hardness, friability, disintegration, and dissolution before any BE step.
• Control moisture: implement drying and packaging controls to match incumbent water content conditions at release.

Process capability as a commercial lever

Better manufacturability converts into:

• higher fill rates during supply stress
• lower batch failures
• faster scale-up transitions across sites
• reduced out-of-spec dissolution risk that can delay launches

---

When does Doral lose exclusivity, and how does excipient IP affect generic entry risk?

Featured snippet answer: Generic entry timing for Doral hinges less on “exclusivity” in the abstract and more on the status of listed patents in the Orange Book for the approved NDA and on Paragraph IV challenge outcomes.

How formulation and excipient IP changes the generic risk profile

For small-molecule tablets, generic risk often comes from:

• listed formulation patents (composition of matter for particular excipient systems)
• method-of-use patents (less relevant if excipient-only changes do not touch MoA)
• method-of-manufacturing patents (granulation or mixing steps)
• process parameter patents where excipient choice is tied to yield and dissolution

Where excipient-linked patents exist, a generic may need to:

• design around excipient composition claims
• use alternate process conditions that avoid method claims
• submit bridging dissolution and stability data that show equivalence despite design-around

---

What patents protect Doral drug product composition, and what is the “excipient design-around” map?

Featured snippet answer: The patent estate for Doral determines whether excipient swaps are “free” or whether they increase litigation exposure and regulatory bridging.

Patent estate types relevant to excipient strategy

1. Tablet composition claims
   • Cover specific combinations of disintegrants, binders, fillers, or solubilizers.
2. Physicochemical or microenvironment claims
   • Claims tied to moisture level, polymorphic form, or stabilization conditions that implicitly involve excipients.
3. Manufacturing method claims
   • Granulation, mixing time, drying endpoint, or roller compaction steps that depend on excipient performance.
4. Coating system claims
   • Film coat excipient composition that affects disintegration and dissolution.

Design-around pathways

• Substitute disintegrant class while matching dissolution similarity and disintegration window.
• Keep binder system constant and move other excipient levers like lubricant or filler to achieve manufacturing robustness.
• Switch lubricant grade under dissolution similarity constraints, then use accelerated stability to show no CQA drift.

---

What is the Orange Book status of Doral (quazepam), and which entries matter for excipient-led competition?

Featured snippet answer: Orange Book “listed drug product” information is the practical gate for excipient strategy because it defines whether formulation-related patents constrain generic reformulation and 505(b)(2) supplements.

Entries that determine launch feasibility

• NDA listed patents by patent number
• dosage form and strength
• expiration dates
• use code and patent type (drug substance vs drug product vs method-of-use)
• reference to patents covering specific excipient systems

---

Which generic or 505(b)(2) strategies create the biggest commercial upside for quazepam based on excipient differentiation?

Featured snippet answer: The highest-upside differentiation is “manufacturing and supply reliability” excipient strategy, not therapeutic differentiation.

Commercial opportunity clusters

1. Supply gap capture
   • Firms with validated alternate manufacturing using excipient systems that reduce batch failure can win formulary placement during shortages.
2. Site expansion launches
   • A second manufacturing site that can reliably meet dissolution and stability specs earns incremental volume and reduces buyer risk.
3. Strength or package line extensions
   • Excipient platform reuse across strength SKUs reduces COGS and supports faster commercial rollouts.
4. Cost-down via excipient optimization
   • Switching to lower-cost excipient grades that preserve dissolution can reduce per-tablet cost while maintaining spec compliance.

Where excipient differentiation is most valued

• hospitals and payers care about consistent supply and stable product performance
• regulators care about dissolution, stability, and BE comparability
• manufacturers care about yield and OOS reduction

---

How strong is the patent estate for Doral excipient and solid oral processing claims?

Featured snippet answer: Patent estate strength is strongest when drug product patents explicitly cover excipient systems or when manufacturing method claims tie to those systems.

Strength indicators used in real-world diligence

• number of listed drug product patents
• how broad the claims are around excipient categories vs. specific compositions
• presence of continuation activity that extends enforcement windows
• whether courts have previously construed similar excipient-related claims (litigation history)

Implication for investment and licensing

If formulation patents broadly claim excipient combinations, the commercial target should shift toward:

• licensing the incumbent formulation platform
• acquiring rights to patents that enable safe excipient substitutions
• building a noninfringing process route that maintains dissolution similarity without stepping on method claims

---

What excipient-linked formulation changes are most likely to trigger bioequivalence failure for quazepam tablets?

Featured snippet answer: Changes that alter dissolution rate, disintegration mechanics, or moisture behavior are most likely to break BE.

High-risk change categories

• changing disintegrant class or particle size distribution
• altering magnesium stearate level or lubricant system
• shifting from wet granulation to direct compression (or vice versa) without bridging dissolution equivalence
• modifying coating excipient system that changes disintegration or dissolution time

BE impact pathways

• altered wettability changes initial dissolution slope
• altered porosity changes water penetration and disintegration kinetics
• altered stability changes impurity profile and potentially active concentration

---

What patent litigation affects generic entry for Doral, and where do excipients show up in disputes?

Featured snippet answer: Litigation most often turns on whether generics’ formulation and manufacturing methods fall within excipient-anchored drug product claims.

Litigation factors that matter for excipient strategy

• claim scope: are excipients defined broadly (functional language) or narrowly (specific lists)?
• whether generic applicants changed excipient identity or merely adjusted concentrations
• whether they used alternate granulation methods tied to excipient behavior
• whether courts accepted arguments for noninfringement based on compositional differences

---

How do settlement agreements and licensing deals typically address excipient and process design-around?

Featured snippet answer: Settlements often enforce launch timing and may require noninfringing formulation commitments, including constraints on excipient systems and manufacturing methods.

Common settlement mechanisms

• delayed launch date tied to patent expiration
• covenant not to market under certain formulation versions
• binding formulation commitments that reduce claim overlap
• stipulations regarding dissolution similarity or impurity profiles

---

What is the best excipient strategy for a new 505(b)(2) or NDA supplement product containing quazepam?

Featured snippet answer: Use an excipient platform that matches known dissolution and stability performance, then justify bridging through dissolution similarity and stability comparability rather than making multiple simultaneous excipient changes.

Practical development pathway

• start from a baseline formulation platform with similar disintegration and dissolution behavior
• change one variable at a time (especially disintegrant and lubricant)
• align dissolution profile across relevant media
• run accelerated stability to ensure CQA stability consistency
• finalize packaging system to maintain water content parity

---

How does Doral excipient strategy compare with other benzodiazepine hypnotics for commercialization lessons?

Featured snippet answer: Most benzodiazepine hypnotic oral solids face the same excipient sensitivities: dissolution slope, disintegration mechanics, and moisture stability. Doral’s commercial outcomes likely mirror that pattern.

What transfers across products

• lubricant hydrophobicity effects on dissolution
• moisture-control dependence for stability and impurity growth
• disintegrant selection as the biggest early dissolution lever

What differs

• quazepam-specific solubility and pH dependence
• incumbent formulation release specs (dissolution method sensitivity)
• any listed patents explicitly covering excipient systems or manufacturing methods

---

Key commercial scenarios for quazepam tablets driven by excipient and manufacturing strategy

Scenario 1: Low-OOS excipient platform for cost-down and supply security

• Target COGS reduction via excipient-grade optimization and reduced tablet defects.
• Deliver consistent dissolution and stability to avoid rejections that delay shipments.

Scenario 2: Design-around for accelerated generic launch

• Map excipient and method claims to identify safe substitution space.
• Build dissolution similarity package to de-risk BE and mitigate post-approval disputes.

Scenario 3: Licensing formulation IP

• Acquire rights if formulation patents are broad enough that redesign risks litigation.
• Commercial advantage comes from faster time-to-market with fewer bridging iterations.

---

Key Takeaways

• Excipient strategy for Doral (quazepam) is primarily a bioequivalence and manufacturability problem, not a mechanism-of-action problem.
• Highest change-sensitive excipients are typically disintegrants, solubilizers/surfactants (if used), lubricants (grade and level), and moisture-control components.
• Commercial upside is strongest in supply reliability, reduced batch failures, and faster scaling across manufacturing sites using excipient systems aligned to incumbent dissolution and stability expectations.
• Patent estate strength matters when claims explicitly cover excipient compositions or solid oral processing methods, shaping whether excipient swaps create litigation and bridging risk.
• The most actionable route for entrants is a controlled excipient equivalence map backed by dissolution similarity and stability comparability, paired with a claim-by-claim design-around assessment grounded in Orange Book listings.

---

FAQs

1. Which excipient swaps for quazepam tablets most frequently require dissolution bridging studies?
2. How does magnesium stearate grade and concentration affect dissolution and BE risk for benzodiazepine hypnotics like quazepam?
3. What packaging and moisture-control excipient strategy best protects quazepam stability over shelf life?
4. What Orange Book patent types most constrain formulation changes for small-molecule solid oral products?
5. When are excipient-linked method-of-manufacturing patents more relevant than drug-product composition patents for generic challengers?

---

References

(No sources were provided in the prompt, and no Doral/Orange Book/patent specifics were included in the user request.)